申联生物预亏2000万二股东套现1.11亿 拟2.37亿并购创新药企业

Core Viewpoint - The company Shunlian Bio (688098.SH) is expanding into the human pharmaceutical sector through an acquisition of a controlling stake in Yangzhou Shizhiyuan Biotechnology Co., Ltd. (Shizhiyuan) to address competitive pressures in its existing animal health business [1][6] Group 1: Acquisition Details - Shunlian Bio plans to acquire a controlling stake in Shizhiyuan for 237 million yuan through its wholly-owned subsidiary, Shanghai Bentiangcheng Biomedical Co., Ltd. [1][3] - The acquisition involves a payment of 31.44 million yuan for a portion of Shizhiyuan's registered capital and an additional investment of 206 million yuan for new registered capital, resulting in Shunlian holding 40.65% of Shizhiyuan [3][5] - After the acquisition, Shunlian and its concerted parties will collectively hold 51% of Shizhiyuan, allowing Shunlian to control the voting rights [5] Group 2: Financial Performance and Projections - Shunlian Bio is facing significant pressure in its animal health business, with expectations of a net loss of 20 million yuan in 2025, marking its first loss since going public [1][7] - The company has experienced declining performance over the past four years, with a projected net loss of 20 million yuan and a decrease in revenue and gross margin due to competitive pressures in the animal health sector [7][8] - Shizhiyuan, the target of the acquisition, has not yet turned a profit, with projected revenues of 164,300 yuan in 2024 and 2.53 million yuan in 2025, alongside net losses of 15.65 million yuan and 12.94 million yuan respectively [5][6] Group 3: Strategic Shift - The acquisition is part of Shunlian's strategy to diversify into human pharmaceuticals, aiming to leverage Shizhiyuan's capabilities in innovative drug development [6][8] - The company intends to create a synergistic business model combining human pharmaceuticals and animal health, enhancing its research and development pipeline in the human drug sector [6][7] - Shunlian is also adjusting its operational strategies to focus on customer needs and improve internal management efficiency amid declining sales and increased credit losses [7][8]